Abstract
Background Anti-Platelet Factor 4 (PF4) IgG antibodies that activate platelets via FcγRIIa have been shown to be an important part of the pathophysiology of vaccine-induced immune thrombocytopenia and thrombosis (VITT). There is now extensive literature on its presentation and initial management. There is no literature however on what happens to these patients following discharge.
Methods We collected clinical data and samples from seven patients presenting with VITT and followed them up for 82-145 days. We also collected clinical samples from them at last follow-up. Testing for anti-PF4/heparin antibodies was done using an anti-PF4/heparin enzymatic immunoassay. Flow Cytometry was used to look at FcγRIIa levels on patient platelets. Light Transmission Aggregometry with patient serum and healthy donor / patient platelets was used to analyse platelet responsiveness, in the presence and absence of PF4.
Findings All patients were discharged on direct oral anticoagulants. Two patients remain completely symptom free, three have ongoing headaches, two have residual neurological deficits. Two patients developed mild thrombocytopenia and worsening headache (but without cerebral venous sinus thrombosis) and were retreated, one of these with rituximab. All patients, except the one treated with rituximab, had similar anti-PF4 antibody titres at 80-120 days to their levels at diagnosis. Platelets from patients at follow-up had normal levels of FcγRIIa and had normal responses to thrombin and collagen-related-peptide. Patient serum from diagnosis strongly activated healthy donor platelets in the presence of PF4. Serum from follow-up was much weaker at stimulating platelets, even in the presence of PF4.
Interpretation This study shows that despite similar PF4 antibody titres at diagnosis and during follow-up, there are further differences in patient serum, that are not apparent from currently used testing, that result in lower levels of platelet activation during the follow-up period. Further understanding of these factors are important in order to assess duration of anticoagulation for these patients.
Funding This work was supported by an Accelerator Grant (AA/18/2/34218) from the British Heart Foundation (BHF) and by a National Institute for Health Research (NIHR) grant.
Key points
PF4 antibody titres do not reduce up to 4-months post ChAdOx1 nCoV-19 in patients with VITT
Despite similar PF4 antibody titres, diagnostic serum is more potent at activating platelets in the presence of PF4 than follow-up serum.
Competing Interest Statement
PLRN and SPW have received research grants from Novartis, Principia and Rigel Pharmaceuticals. PLRN has had honoraria from Bayer, Grifols and Takeda.
Funding Statement
This work was supported by an Accelerator Grant (AA/18/2/34218) from the British Heart Foundation (BHF) and a National Institute for Health Research (NIHR) grant. SPW holds a BHF Chair (CH03/003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients presenting with thrombosis and thrombocytopenia, occurring after AZD1222 vaccination were recruited. Informed consent was provided by the patients or by their next of kin in those who lacked capacity. Collection of blood from these patients (including those lacking capacity) was approved under research ethics granted to the University of Birmingham Human Biomaterial Resource Centre (North West, Haydock Research Ethics Committee, reference: 15/NW/0079, amendment 3, 19/11/2018). Ethical approval for collecting blood from healthy volunteers was granted by Birmingham University Internal Ethical Review Committee (reference: ERN_11-0175, assessed 22/3/2021). All studies were performed in line with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual participant data will not be made available.
